Co-Diagnostics Gets Order for Coronavirus Screening Test
2:32 pm ET February 10, 2020 (Dow Jones) Print
By Josh Beckerman
Co-Diagnostics Inc. (CODX) said it received an order for its new coronavirus screening test that calls for delivery to various international markets.
The order included payment for the initial shipment of assays.
Co-Diagnostics shares, which were briefly paused due to volatility, recently traded up 18% to $3.55.
The company said last week that its "research use only" CoPrimer test for the 2019-nCoV coronavirus was ready for sale to appropriate laboratories, hospitals, and institutions.
Shares of vaccine and diagnostics companies have been active during the coronavirus outbreak. On Jan. 22, Co-Diagnostics closed at $1.13.
The company said Monday that "our mandate includes supporting as many markets as possible in a public health crisis, and taking a test from design to commercialization in under three weeks underscores this commitment."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
February 10, 2020 14:32 ET (19:32 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.